Immuno-oncological drugs application in the treatment of metastatic cutaneous melanoma with lymph nodes metastases of rare localization: a case report
A. P. Polyakov,
L. V. Bolotina,
A. L. Kornietskaya,
D. S. Kudashkina,
D. V. Sidorov,
A. A. Troitskiy,
A. R. Gevorkov https://doi.org/10.17650/2222-1468-2022-12-1-114-119
Abstract
Cutaneous melanoma is characterized by an aggressive course associated with a tendency to metastasis. For a long time, the prognosis of patients with metastatic melanoma remained extremely poor. However, the introduction of immunooncological drugs into clinical practice has changed the approaches to the treatment of patients with metastatic melanoma, and fundamentally improved the prognosis and quality of life of such patients, which undoubtedly became a breakthrough in the treatment of this pathology. This article presents a clinical case of the treatment with immunological drugs of a patient with metastatic melanoma of the skin with lymph nodes of rare localization with a complete tumor response.
About the Authors
A. P. Polyakov
P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
A. P. Polyakov
Moscow
L. V. Bolotina
P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
L. V. Bolotina
Moscow
A. L. Kornietskaya
P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
A. L. Kornietskaya
Moscow
D. S. Kudashkina
P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
Daria Sergeevna Kudashkina
Moscow
D. V. Sidorov
P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
D. V. Sidorov
Moscow
A. A. Troitskiy
P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
A. A. Troitskiy
Moscow
A. R. Gevorkov
P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
A. R. Gevorkov
Moscow
References
1. Malignant tumors in Russia in 2019 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinskii, A.O. Shakhzadova. Moscow: P.A. Herzen MNIOI – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of the Russia, 2020. 252 p. (In Russ.).
2. Cummins D.L., Cummins J.M., Pantle H. et al. Cutaneous malignant melanoma. Mayo Clin Proc 2006;81(4):500–7. DOI: 10.4065/81.4.500.
3. Scott J.F., Gerstenblith M.R. Melanoma of unknown primary. In: Noncutaneous melanoma. Brisbane: Codon Publications, 2018. Pp. 99–117. DOI: 10.15586/codon.noncutaneousmelanoma.2018.ch7.
4. Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol;2012;2012:647684–9. DOI: 10.1155/2012/647684.
5. Liang K.V., Sanderson S.O., Nowakowski G.S. et al. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 2006;81(4):511–6. DOI: 10.4065/81.4.511.
6. Park J.-S., Ng K.-S., Saw R.P.M. et al. Metastatic melanoma to the colon, rectum, and anus: A 50-year experience. Ann Surg Oncol 2018;25(8):2178–83. DOI: 10.1245/s10434-018-6451-4.
7. Polyakov A.P., Rebrikova I.V., Mordovskiy A.V. Current treatment strategy for resectable scalp and neck melanoma. Opukholi golovy i shei = Head and Neck Tumors 2021; 11(2):50–6. (In Russ.). DOI: 10.17650/2222-1468-2021-11-2-50-56.
8. Sanki A., Scolyer R.A., Thompson J.F. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 2009;35(3):313–9. DOI: 10.1016/j.ejso.2008.04.011.
9. Deutsch G.B., Flaherty D.C., Kirchoff D.D. Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965–2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy. JAMA Surg 2017;152(7):672–678. DOI: 10.1001/jamasurg.2017.0459.
10. Polyakov A.P., Mordovskiy A.V. Current therapy strategy for metastatic BRAF-positive cutaneous melanoma. Farmateka = Pharmateca 2020;11:14–20 (In Russ.). DOI: 10.18565/pharmateca.2020.11.14-20.
11. Nazarian R., Shi H., Wang Q. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326):973–7. DOI: 10.1038/nature09626.
12. Clinical recommendations “Melanoma of the skin and mucous membranes”, 2020. (Approved by the Ministry of Health of Russia). Available at: https://legalacts.ru/doc/klinicheskie-rekomendatsiimelanomakozhi-i-slizistykh-obolochekutvminzdravom_3/. (In Russ.).
13. Stroyakovskiy D.L., Abramov M.E., Demidov L.V. et al. Practical recommendations on cutaneus melanoma drug treatment. Zlokachestvennye opukholi = Malignant tumors 2021;11(3s2-1):244–63. (In Russ.). DOI: 10.18027/2224-5057-2021-11-3s2-16.
14. Wolchok J.D., Chiarion-Sileni V., Gonzalez R. et al. CheckMate 067: 6.5year outcomes in patients (pts) with advanced melanoma. J Clin Oncol 2021;39(15):9506. DOI: 10.1200/JCO.2021.39.15_suppl.9506.
Review
For citations:
Polyakov A.P., Bolotina L.V., Kornietskaya A.L., Kudashkina D.S., Sidorov D.V., Troitskiy A.A., Gevorkov A.R. Immuno-oncological drugs application in the treatment of metastatic cutaneous melanoma with lymph nodes metastases of rare localization: a case report. Head and Neck Tumors (HNT). 2022;12(1):114-119. (In Russ.) https://doi.org/10.17650/2222-1468-2022-12-1-114-119
Views:
413
Email this article 